<DOC>
	<DOCNO>NCT00252707</DOCNO>
	<brief_summary>In study , among patient non-small cell lung cancer , metastasis recurrence previous treatment chemotherapy receive gefitinib docetaxel , compare effectiveness safety gefitinib docetaxel .</brief_summary>
	<brief_title>Iressa 2nd Line Phase III Study Japan</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>You `` histologically '' `` cytologically '' confirm recurrent metastatic NSCLC You treat chemotherapy include platinum NSCLC . You receive treatment nonsmall lung cancer within 4 week participation study ( except specific therapy ) You disease acute lung injury , idiopathic pulmonary fibrosis , pulmonary pneumonia , pneumoconiosis evident Xray You disease radiation pneumonia druginduced pneumonia , require treatment corticosteroid</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
</DOC>